Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's Disease.
暂无分享,去创建一个
Li Lin | P. Lograsso | M. Cameron | Y. Ling | T. Kamenecka | J. Chambers | Claudia H. Ruiz | Derek Duckett | Ted Kamenecka | M. Ganno | Yuan Yuan Ling | Xinyi Song | Michael D Cameron | Derek R Duckett | Jeremy W Chambers | Alok Pachori | Shannon Howard | Michelle Ganno | Donald Hansen | Weimin Chen | Lisa Cherry | Claudia H Ruiz | Philip Lograsso | A. Pachori | Li Lin | D. Duckett | Xinyi Song | L. Cherry | S. Howard | Weimin Chen | D. Hansen
[1] David S. Park,et al. Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease , 2003, The Journal of Neuroscience.
[2] P. Lograsso,et al. Structure-Activity Relationships and X-ray Structures Describing the Selectivity of Aminopyrazole Inhibitors for c-Jun N-terminal Kinase 3 (JNK3) over p38* , 2009, Journal of Biological Chemistry.
[3] T. Dawson,et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[4] P. Lograsso,et al. Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. , 2010, Journal of medicinal chemistry.
[5] Ming-tao Li,et al. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson’s disease , 2004, Neuroscience Research.
[6] A. Lang,et al. Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.
[7] Ted M. Dawson,et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.
[8] Y. Oh,et al. A distinct death mechanism is induced by 1-methyl-4-phenylpyridinium or by 6-hydroxydopamine in cultured rat cortical neurons: degradation and dephosphorylation of tau , 2003, Neuroscience Letters.
[9] Werner Poewe,et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. , 2009, The New England journal of medicine.
[10] Pasko Rakic,et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[11] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[12] M. Schwarzschild,et al. The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures. , 2001, Parkinsonism & related disorders.
[13] T. Joh,et al. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo , 2004, Neurobiology of Disease.
[14] J. Bilsland,et al. Caspase Inhibitors Attenuate 1-Methyl-4-Phenylpyridinium Toxicity in Primary Cultures of Mesencephalic Dopaminergic Neurons , 2002, The Journal of Neuroscience.
[15] M. Beal,et al. Celastrol protects against MPTP‐ and 3‐nitropropionic acid‐induced neurotoxicity , 2005, Journal of neurochemistry.
[16] M. Leist,et al. ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-alpha. , 1997, Immunology letters.
[17] M. Emborg. Evaluation of animal models of Parkinson's disease for neuroprotective strategies , 2004, Journal of Neuroscience Methods.
[18] R. Burke,et al. Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease , 2009, Nature Neuroscience.
[19] P. Lograsso,et al. Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[20] J. Uney,et al. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[21] S. Przedborski,et al. Protocol for the MPTP mouse model of Parkinson's disease , 2007, Nature Protocols.
[22] Jos Prickaerts,et al. Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway , 2002, Experimental Neurology.
[23] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[24] Denis M. Bayada,et al. Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.
[25] Y. Martin,et al. A bioavailability score. , 2005, Journal of medicinal chemistry.
[26] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[27] R. Obach,et al. Validated assays for human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[28] A. Lang,et al. Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.
[29] Anders Björklund,et al. Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.
[30] Jun Chen,et al. Apoptosis inducing factor mediates caspase‐independent 1‐methyl‐4‐phenylpyridinium toxicity in dopaminergic cells , 2005, Journal of neurochemistry.
[31] Dong-Kug Choi,et al. Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.
[32] P. Lograsso,et al. 3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.